Anteris Technologies secures German clearance to expand PARADIGM heart valve trialProactive Investors · 4 days ago
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory ClearanceGlobeNewsWire · 4 days ago
Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Purchases $1,957,950.10 in StockDefense World · Oct 11, 2026
Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Buys $4,869,897.05 in StockDefense World · Oct 6, 2026
Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Buys $1,838,834.12 in StockDefense World · Oct 6, 2026
Anteris Technologies appoints Brent Moen as chief financial officerProactive Investors - Finance · Sep 7, 2026Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.21 | -$0.30 | Miss |
| May 12, 2026 | -$0.27 | -$0.28 | Miss |
| Mar 11, 2026 | -$0.50 | -$0.74 | Miss |
| Nov 10, 2025 | -$0.54 | -$0.62 | Miss |
| Aug 12, 2025 | -$0.55 | -$0.58 | Miss |
| May 13, 2025 | -$0.49 | -$0.61 | Miss |